A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo

• Published in: Communications Biology Vol. 6; no. 1; pp. 513 - 16
• Main Authors: Havranek, Brandon, Lindsey, Graeme Walker, Higuchi, Yusuke, Itoh, Yumi, Suzuki, Tatsuya, Okamoto, Toru, Hoshino, Atsushi, Procko, Erik, Islam, Shahidul M.
• Format: Journal Article
• Language: English
• Published: London Springer Science and Business Media LLC 12.05.2023; Nature Publishing Group UK; Nature Publishing Group; Nature Portfolio
• Subjects: 631/114/469; 631/154/51/2314; 631/57/2266; 82; 82/80; 82/81; 82/83; 96; 96/31; ACE2; Affinity; Angiotensin-converting enzyme 2; Angiotensin-Converting Enzyme 2 - genetics; Angiotensin-Converting Enzyme 2 - therapeutic use; antibodies; Antibodies, Monoclonal; Biology; Biology (General); Biomedical and Life Sciences; Computer applications; COVID-19; Design; Humans; Life Sciences; Medical Biochemistry; Medical Sciences; Medicine and Health Sciences; monoclonal; Monoclonal antibodies; Protein Engineering; QH301-705.5; SARS-CoV-2; SARS-CoV-2 - genetics; Severe acute respiratory syndrome coronavirus 2; Vaccination

SARS-CoV-2, especially B.1.1.529/omicron and its sublineages, continues to mutate to evade monoclonal antibodies and antibodies elicited by vaccination. Affinity-enhanced soluble ACE2 (sACE2) is an alternative strategy that works by binding the SARS-CoV-2 S protein, acting as a ‘decoy’ to block the...